Clinical Research on First-In-Human Clinical Trial of Transplantation: Regenerative Medicine Using iPS Cell-Derived Neural Stem/Progenitor Cells to Treat Complete Subacute Spinal Cord Injury

Published: January 14, 2022

Office of Communications and Public Relations

January 14, 2022

东京不够热 School of Medicine

东京不够热 Hospital

A group at 东京不够热 Hospital has successfully transplanted human iPS cell-derived neural stem/progenitor cells (iPSC-NS/PCs) into the first participant of a clinical study on regenerative medicine using iPSC-NS/PCs for subacute spinal cord injury (SCI).

For further information, please refer to the following PDF file.

Clinical Research on First-In-Human Clinical Trial of Transplantation: Regenerative Medicine Using iPS Cell-Derived Neural Stem/Progenitor Cells to Treat Complete Subacute Spinal Cord Injury.pdf

Press Release